CAJ | 학술논문

目的：探讨壮肾固精方联合黄芪注射液足三里穴位注射对脾肾气虚型蛋白尿患者的影响。方法45例蛋白尿患者随机分为观察组和对照组，对照组予常规治疗，观察组在对照组基础上予口服壮肾固精方及黄芪注射液足三里穴位注射，观察两组治疗前后24 h尿蛋白定量(24H-UPRO)，、尿微量白蛋白(MAU)、血浆白蛋白(ALB)变化。结果观察组与对照组治疗前年龄、24 h尿蛋白定量、尿微量白蛋白无显著性差异，治疗后观察组24 h尿蛋白定量（977.9±795.4） mg/24 h、尿微量白蛋白（144.6±128.4） mg/L 显著低于对照组（1619.8±1135.4） mg/24 h、（250.0±197.9） mg/L。观察组治疗后的24 h 尿蛋白定量（977.9±795.4） mg/24 h、尿微量白蛋白（144.6±128.4） mg/L较治疗前（1757.8±1113.5） mg/24 h、（369.1±395.5） mg/L）显著降低，而治疗后血浆白蛋白（42.2±5.1） mg/24 h则较治疗前（40.7±6.3） g/L有所升高。结论壮肾固精方联合黄芪注射液足三里穴位注射可有效减少脾肾气虚型蛋白尿患者的蛋白尿。
목적：탐토장신고정방연합황기주사액족삼리혈위주사대비신기허형단백뇨환자적영향。방법45례단백뇨환자수궤분위관찰조화대조조，대조조여상규치료，관찰조재대조조기출상여구복장신고정방급황기주사액족삼리혈위주사，관찰량조치료전후24 h뇨단백정량(24H-UPRO)，、뇨미량백단백(MAU)、혈장백단백(ALB)변화。결과관찰조여대조조치료전년령、24 h뇨단백정량、뇨미량백단백무현저성차이，치료후관찰조24 h뇨단백정량（977.9±795.4） mg/24 h、뇨미량백단백（144.6±128.4） mg/L 현저저우대조조（1619.8±1135.4） mg/24 h、（250.0±197.9） mg/L。관찰조치료후적24 h 뇨단백정량（977.9±795.4） mg/24 h、뇨미량백단백（144.6±128.4） mg/L교치료전（1757.8±1113.5） mg/24 h、（369.1±395.5） mg/L）현저강저，이치료후혈장백단백（42.2±5.1） mg/24 h칙교치료전（40.7±6.3） g/L유소승고。결론장신고정방연합황기주사액족삼리혈위주사가유효감소비신기허형단백뇨환자적단백뇨。
Objective To investigate the efficacy of ZhuangShen GuJingFang combined with injecting Astragalus Injection at Zu-sanli Point on proteinuria patients of Spleen-Kidney Qi Deficiency Type. Methods 45 proteinuria patients who met the study cri-teria were randomly divided into observation group and control group. Two groups received conventional treatment. In addition, the observation group received ZhuangShen GuJingFang and injecting Astragalus Injection at Zusanli Point for two weeks. The changes of 24 hours urine protein (24H-UPRO), microalbuminuria(MAU), plasma-albumin(ALB) of two groups before and after the treat-ment were observed. Results Before the treatment, there were no statistically significant differences in age, 24H-UPRO, MAU be-tween the observation group and the control group, after treatment, the 24H-UPRO, MAU of the observation group was (977.9 ± 795.4 mg/24h), (144.6 ±128.4 mg/L) respectively, which was significantly lower than the control group's (1619.8 ±1135.4mg/24h), (250.0±197.9mg/L) respectively. The 24H-UPRO(977.9±795.4 mg/24h), and MAU(144.6±128.4 mg/L) of the observation group af-ter treatment was much lower than 24H-UPRO (1757.8±1113.5mg/24h), MAU(369.1±395.5mg/L) before treatment, but plasma-al-bumin (42.2±5.1 mg/24h) was higher than that (40.7±6.3 g/L)before the treatment. Conclusion ZhuangShen GuJingFang and in-jecting Astragalus Injection at Zusanli Point benefited proteinuria patients of Spleen-Kidney Qi Deficiency Type.